File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of sucralfate and cimetidine on duodenal ulcer-associated antral gastritis and Campylobacter pylori

TitleEffect of sucralfate and cimetidine on duodenal ulcer-associated antral gastritis and Campylobacter pylori
Authors
Issue Date1989
PublisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/amj
Citation
American Journal Of Medicine, 1989, v. 86 n. 6 A, p. 60-65 How to Cite?
AbstractThe course of gastritis and Campylobacter pylori was studied in a single-blind randomized trial comparing cimetidine 200 mg three times a day and 400 mg at night and sucralfate 1 g four times a day orally for four weeks in 140 patients with proved duodenal ulcer. At least two antral biopsies were performed during endoscopy before entry and at the end of four weeks. The activity and the degree of chronic inflammation, as assessed histologically by the degree of infiltration of, respectively, polymorphs and chronic inflammatory cells, were graded blindly by two pathologists as nil, mild, moderate, or severe. The density of C. pylori, as assessed after Warthin-Starry stain, was similarly graded. Ulcer-healing rates were comparable in the cimetidine (73.2 percent) and sucralfate (79.7 percent) groups. Improvement of the activity of gastritis occurred significantly (p < 0.05) more frequently in the sucralfate (33.3 percent) than in the cimetidine group (18.3 percent), and remained so (p < 0.05) when only patients with healed ulcer were compared. The density of C. pylori decreased significantly in the sucralfate group after treatment (p < 0.01) but not in the cimetidine group. The 12-month ulcer relapse rates were significantly (p < 0.05) lower by life-table analysis in patients healed with sucralfate than in those healed with cimetidine and were unaffected by either the density of Campylobacter in either group or the improvement of the gastritis. It is concluded that sucralfate improves duodenal ulcer-associated antral gastritis and decreases the density of C. pylori, and that factors other than bacterial density and antral gastritis may be responsible for the advantage of sucralfate over cimetidine in ulcer relapse.
Persistent Identifierhttp://hdl.handle.net/10722/147833
ISSN
2015 Impact Factor: 5.61
2015 SCImago Journal Rankings: 2.023
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHui, WMen_HK
dc.contributor.authorLam, SKen_HK
dc.contributor.authorHo, Jen_HK
dc.contributor.authorNg, Ien_HK
dc.contributor.authorLau, WYen_HK
dc.contributor.authorBranicki, FJen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorFong Lok, ASen_HK
dc.contributor.authorNg, MMTen_HK
dc.contributor.authorFok, Jen_HK
dc.contributor.authorPoon, GPen_HK
dc.contributor.authorChoi, TKen_HK
dc.date.accessioned2012-05-29T06:09:28Z-
dc.date.available2012-05-29T06:09:28Z-
dc.date.issued1989en_HK
dc.identifier.citationAmerican Journal Of Medicine, 1989, v. 86 n. 6 A, p. 60-65en_HK
dc.identifier.issn0002-9343en_HK
dc.identifier.urihttp://hdl.handle.net/10722/147833-
dc.description.abstractThe course of gastritis and Campylobacter pylori was studied in a single-blind randomized trial comparing cimetidine 200 mg three times a day and 400 mg at night and sucralfate 1 g four times a day orally for four weeks in 140 patients with proved duodenal ulcer. At least two antral biopsies were performed during endoscopy before entry and at the end of four weeks. The activity and the degree of chronic inflammation, as assessed histologically by the degree of infiltration of, respectively, polymorphs and chronic inflammatory cells, were graded blindly by two pathologists as nil, mild, moderate, or severe. The density of C. pylori, as assessed after Warthin-Starry stain, was similarly graded. Ulcer-healing rates were comparable in the cimetidine (73.2 percent) and sucralfate (79.7 percent) groups. Improvement of the activity of gastritis occurred significantly (p < 0.05) more frequently in the sucralfate (33.3 percent) than in the cimetidine group (18.3 percent), and remained so (p < 0.05) when only patients with healed ulcer were compared. The density of C. pylori decreased significantly in the sucralfate group after treatment (p < 0.01) but not in the cimetidine group. The 12-month ulcer relapse rates were significantly (p < 0.05) lower by life-table analysis in patients healed with sucralfate than in those healed with cimetidine and were unaffected by either the density of Campylobacter in either group or the improvement of the gastritis. It is concluded that sucralfate improves duodenal ulcer-associated antral gastritis and decreases the density of C. pylori, and that factors other than bacterial density and antral gastritis may be responsible for the advantage of sucralfate over cimetidine in ulcer relapse.en_HK
dc.languageengen_US
dc.publisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/amjen_HK
dc.relation.ispartofAmerican Journal of Medicineen_HK
dc.subject.meshAdulten_US
dc.subject.meshCampylobacter - Isolation & Purificationen_US
dc.subject.meshCampylobacter Infections - Complications - Microbiology - Pathologyen_US
dc.subject.meshChronic Diseaseen_US
dc.subject.meshCimetidine - Therapeutic Useen_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshDuodenal Ulcer - Complications - Pathologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshGastritis - Drug Therapy - Etiology - Microbiology - Pathologyen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshPyloric Antrum - Microbiology - Pathologyen_US
dc.subject.meshRandom Allocationen_US
dc.subject.meshRecurrenceen_US
dc.subject.meshSucralfate - Therapeutic Useen_US
dc.titleEffect of sucralfate and cimetidine on duodenal ulcer-associated antral gastritis and Campylobacter pylorien_HK
dc.typeArticleen_HK
dc.identifier.emailNg, I:iolng@hkucc.hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityNg, I=rp00335en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid2660558-
dc.identifier.scopuseid_2-s2.0-0024342195en_HK
dc.identifier.volume86en_HK
dc.identifier.issue6 Aen_HK
dc.identifier.spage60en_HK
dc.identifier.epage65en_HK
dc.identifier.isiWOS:A1989AE02800013-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridHui, WM=7103196477en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK
dc.identifier.scopusauthoridHo, J=15029093800en_HK
dc.identifier.scopusauthoridNg, I=7102753722en_HK
dc.identifier.scopusauthoridLau, WY=7402933199en_HK
dc.identifier.scopusauthoridBranicki, FJ=7003617514en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridFong Lok, AS=35379868500en_HK
dc.identifier.scopusauthoridNg, MMT=24454037400en_HK
dc.identifier.scopusauthoridFok, J=36829449900en_HK
dc.identifier.scopusauthoridPoon, GP=24788065400en_HK
dc.identifier.scopusauthoridChoi, TK=7202770029en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats